BETR.CN

BetterLife Pharma Inc.

US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives

VANCOUVER, British Columbia, Nov. 15, 2023 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that its patent application for BETR-001 and LSD d... Read More...

BetterLife Pharma to Host Investors Update Call on September 18, 2023

BetterLife Pharma Inc.VANCOUVER, British Columbia, Sept. 14, 2023 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announces that it will host an invest... Read More...

BetterLife Announces Offering of Units

<!-- Name:DistributionId Value:8783646 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 --> <!-- Name:CustomerId Value:1216524 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:2b7cca25-ad23-435f-b4ab-5d49209e3a38 --> NOT FOR DISTRI... Read More...

BetterLife Pharma Strengthens Board of Directors

VANCOUVER, Dec. 28, 2020 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that it has added Mr. Sergei Stetsenko to its Board of Directors to prepare for its growth phase in psychedelic medicines. Mr. Stetsenko is a financier and venture cap... Read More...